Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation
Open accessThe DOI matches its Crossref record.
Abstract
Multiple endocrine neoplasia type 2 (MEN 2) is a dominantly inherited cancer syndrome that comprises three clinical subtypes: MEN type 2A (MEN-2A), MEN type 2B (MEN-2B), and familial medullary thyroid carcinoma (FMTC). Medullary thyroid carcinoma (MTC), a malignant tumor arising from calcitonin-secreting thyroid C cells, is the cardinal disease feature of this syndrome, and mortality in affected MEN-2 patients is mainly caused by this malignancy. Germ-line mutations of the RET protooncogene, which encodes a receptor tyrosine kinase, are responsible for these three neoplastic-prone disorders. MEN2 mutations convert the RET protooncogene in a dominantly acting oncogene as a consequence of the ligand-independent activation of the tyrosine kinase. The majority of MEN2A and FMTC mutations are located in the extracellular domain and cause the replacement of one of five juxtamembrane cysteines by a different amino acid. To examine whether expression of a MEN2A allele of RET results in transformation of C cells, we have used the transgenic approach. Expression of the RET gene altered by a MEN2A mutation was targeted in C cells by placing the transgene under the control of the calcitonin gene-related peptide/calcitonin promoter. Animals of three independent transgenic mouse lines, which expressed the transgene in the thyroid, displayed overt bilateral C cell hyperplasia as early as 3 weeks of age and subsequently developed multifocal and bilateral MTC. Moreover, these tumors were morphologically and biologically similar to human MTC which afflicts MEN- 2 individuals. These findings provide evidence that the MEN2A mutant form of RET is oncogenic in parafollicular C cells and suggest that these transgenic mice should prove a valuable animal model for hereditary MTC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3298 · Cited by 684
Early Malignant Progression of Hereditary Medullary Thyroid Cancer
Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., van Vroonhoven, T. J., Roeher, H.-D., Wahl, R. A., Lamesch, P., Raue, F., Conte-Devolx, B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa012915 · Cited by 545
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
The GDNF/RET signaling pathway and human diseases
Takahashi, M. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00012-0 · Cited by 446
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 406
Metadata
- Authors
- Michiels, F.-M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G. M., Feunteun, J., & Billaud, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-04
- Volume
- 94
- Issue
- 7
- Pages
- 3330-3335
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2032457962
- Cited by
- 140
- References
- 0
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. https://app.cochat.ai/papers/10.1073/pnas.94.7.3330
- The paper
- Michiels, F.-M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G. M., Feunteun, J., & Billaud, M. (1997). Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.94.7.3330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.